nodes	percent_of_prediction	percent_of_DWPC	metapath
Lapatinib—ERBB2—esophageal cancer	0.459	0.618	CbGaD
Lapatinib—EGFR—esophageal cancer	0.217	0.293	CbGaD
Lapatinib—ABCB1—esophageal cancer	0.066	0.0889	CbGaD
Lapatinib—ERBB2—exocrine gland—esophageal cancer	0.00583	0.101	CbGeAlD
Lapatinib—Gefitinib—SBK1—esophageal cancer	0.00419	0.627	CrCbGaD
Lapatinib—Metastatic neoplasm—Cisplatin—esophageal cancer	0.00384	0.0837	CcSEcCtD
Lapatinib—ERBB2—neck—esophageal cancer	0.00373	0.0646	CbGeAlD
Lapatinib—TAP1—bronchus—esophageal cancer	0.00342	0.0592	CbGeAlD
Lapatinib—PIK3C2B—bronchus—esophageal cancer	0.00321	0.0556	CbGeAlD
Lapatinib—TAP1—trachea—esophageal cancer	0.00307	0.0532	CbGeAlD
Lapatinib—PIK3C2B—trachea—esophageal cancer	0.00288	0.0499	CbGeAlD
Lapatinib—ERBB2—epithelium—esophageal cancer	0.00254	0.0439	CbGeAlD
Lapatinib—ERBB4—epithelium—esophageal cancer	0.00254	0.0439	CbGeAlD
Lapatinib—ERBB2—smooth muscle tissue—esophageal cancer	0.00244	0.0423	CbGeAlD
Lapatinib—PI4KB—bronchus—esophageal cancer	0.00234	0.0405	CbGeAlD
Lapatinib—Paronychia—Methotrexate—esophageal cancer	0.00233	0.0508	CcSEcCtD
Lapatinib—PI4KB—smooth muscle tissue—esophageal cancer	0.00229	0.0396	CbGeAlD
Lapatinib—TAP1—lung—esophageal cancer	0.00221	0.0382	CbGeAlD
Lapatinib—PI4KB—trachea—esophageal cancer	0.0021	0.0364	CbGeAlD
Lapatinib—PIK3C2B—lung—esophageal cancer	0.00207	0.0359	CbGeAlD
Lapatinib—ERBB2—digestive system—esophageal cancer	0.00193	0.0334	CbGeAlD
Lapatinib—Peripheral sensory neuropathy—Capecitabine—esophageal cancer	0.0019	0.0414	CcSEcCtD
Lapatinib—Gefitinib—CHEK2—esophageal cancer	0.00163	0.245	CrCbGaD
Lapatinib—ERBB2—lung—esophageal cancer	0.00161	0.0279	CbGeAlD
Lapatinib—ERBB4—lung—esophageal cancer	0.00161	0.0279	CbGeAlD
Lapatinib—TAP1—lymph node—esophageal cancer	0.00151	0.0261	CbGeAlD
Lapatinib—PI4KB—lung—esophageal cancer	0.00151	0.0261	CbGeAlD
Lapatinib—PIK3C2B—lymph node—esophageal cancer	0.00142	0.0245	CbGeAlD
Lapatinib—EGFR—lung—esophageal cancer	0.00137	0.0237	CbGeAlD
Lapatinib—ERBB2—lymph node—esophageal cancer	0.0011	0.0191	CbGeAlD
Lapatinib—PI4KB—lymph node—esophageal cancer	0.00103	0.0179	CbGeAlD
Lapatinib—Mucosal inflammation—Capecitabine—esophageal cancer	0.00098	0.0214	CcSEcCtD
Lapatinib—Hepatotoxicity—Cisplatin—esophageal cancer	0.000953	0.0208	CcSEcCtD
Lapatinib—EGFR—lymph node—esophageal cancer	0.000935	0.0162	CbGeAlD
Lapatinib—Infection—Carboplatin—esophageal cancer	0.000889	0.0194	CcSEcCtD
Lapatinib—Nail disorder—Capecitabine—esophageal cancer	0.000837	0.0182	CcSEcCtD
Lapatinib—Haemoglobin decreased—Capecitabine—esophageal cancer	0.000788	0.0172	CcSEcCtD
Lapatinib—Mucosal inflammation—Methotrexate—esophageal cancer	0.00073	0.0159	CcSEcCtD
Lapatinib—Hepatotoxicity—Capecitabine—esophageal cancer	0.000703	0.0153	CcSEcCtD
Lapatinib—Gefitinib—EGFR—esophageal cancer	0.000653	0.0979	CrCbGaD
Lapatinib—Nail disorder—Methotrexate—esophageal cancer	0.000623	0.0136	CcSEcCtD
Lapatinib—CYP2C19—digestive system—esophageal cancer	0.000601	0.0104	CbGeAlD
Lapatinib—Hyperbilirubinaemia—Capecitabine—esophageal cancer	0.000597	0.013	CcSEcCtD
Lapatinib—Renal failure acute—Cisplatin—esophageal cancer	0.000579	0.0126	CcSEcCtD
Lapatinib—Blood bilirubin increased—Capecitabine—esophageal cancer	0.000574	0.0125	CcSEcCtD
Lapatinib—Interstitial lung disease—Methotrexate—esophageal cancer	0.000571	0.0124	CcSEcCtD
Lapatinib—Hepatotoxicity—Methotrexate—esophageal cancer	0.000523	0.0114	CcSEcCtD
Lapatinib—Dehydration—Cisplatin—esophageal cancer	0.000497	0.0108	CcSEcCtD
Lapatinib—CYP3A5—digestive system—esophageal cancer	0.000473	0.0082	CbGeAlD
Lapatinib—Hyperbilirubinaemia—Methotrexate—esophageal cancer	0.000444	0.00969	CcSEcCtD
Lapatinib—Renal failure acute—Capecitabine—esophageal cancer	0.000427	0.00931	CcSEcCtD
Lapatinib—Hot flush—Capecitabine—esophageal cancer	0.000421	0.00918	CcSEcCtD
Lapatinib—Menopausal symptoms—Capecitabine—esophageal cancer	0.000417	0.0091	CcSEcCtD
Lapatinib—Neuropathy peripheral—Cisplatin—esophageal cancer	0.000404	0.0088	CcSEcCtD
Lapatinib—Cardiac failure—Capecitabine—esophageal cancer	0.000404	0.0088	CcSEcCtD
Lapatinib—Stomatitis—Cisplatin—esophageal cancer	0.000401	0.00875	CcSEcCtD
Lapatinib—CYP3A5—lung—esophageal cancer	0.000395	0.00684	CbGeAlD
Lapatinib—Pain in extremity—Capecitabine—esophageal cancer	0.000394	0.00859	CcSEcCtD
Lapatinib—Hepatobiliary disease—Cisplatin—esophageal cancer	0.000389	0.00849	CcSEcCtD
Lapatinib—Dehydration—Capecitabine—esophageal cancer	0.000366	0.00799	CcSEcCtD
Lapatinib—Connective tissue disorder—Cisplatin—esophageal cancer	0.000363	0.00792	CcSEcCtD
Lapatinib—Dry skin—Capecitabine—esophageal cancer	0.000361	0.00787	CcSEcCtD
Lapatinib—CYP3A4—digestive system—esophageal cancer	0.000355	0.00615	CbGeAlD
Lapatinib—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.000347	0.00758	CcSEcCtD
Lapatinib—Cardiac disorder—Cisplatin—esophageal cancer	0.000343	0.00748	CcSEcCtD
Lapatinib—Immune system disorder—Cisplatin—esophageal cancer	0.000334	0.00728	CcSEcCtD
Lapatinib—Mediastinal disorder—Cisplatin—esophageal cancer	0.000333	0.00727	CcSEcCtD
Lapatinib—ABCB1—epithelium—esophageal cancer	0.000331	0.00572	CbGeAlD
Lapatinib—Alopecia—Cisplatin—esophageal cancer	0.000327	0.00712	CcSEcCtD
Lapatinib—Malnutrition—Cisplatin—esophageal cancer	0.000322	0.00702	CcSEcCtD
Lapatinib—Neutropenia—Capecitabine—esophageal cancer	0.000318	0.00694	CcSEcCtD
Lapatinib—Renal failure acute—Methotrexate—esophageal cancer	0.000318	0.00693	CcSEcCtD
Lapatinib—Pneumonia—Capecitabine—esophageal cancer	0.000305	0.00666	CcSEcCtD
Lapatinib—Infestation NOS—Capecitabine—esophageal cancer	0.000304	0.00662	CcSEcCtD
Lapatinib—Infestation—Capecitabine—esophageal cancer	0.000304	0.00662	CcSEcCtD
Lapatinib—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000298	0.00649	CcSEcCtD
Lapatinib—Anaemia—Cisplatin—esophageal cancer	0.000297	0.00649	CcSEcCtD
Lapatinib—Stomatitis—Capecitabine—esophageal cancer	0.000296	0.00645	CcSEcCtD
Lapatinib—ABCB1—trachea—esophageal cancer	0.000292	0.00506	CbGeAlD
Lapatinib—Leukopenia—Cisplatin—esophageal cancer	0.000288	0.00628	CcSEcCtD
Lapatinib—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000287	0.00626	CcSEcCtD
Lapatinib—Epistaxis—Capecitabine—esophageal cancer	0.000286	0.00624	CcSEcCtD
Lapatinib—Myalgia—Cisplatin—esophageal cancer	0.000274	0.00598	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000272	0.00593	CcSEcCtD
Lapatinib—Connective tissue disorder—Capecitabine—esophageal cancer	0.000268	0.00584	CcSEcCtD
Lapatinib—Anaphylactic shock—Cisplatin—esophageal cancer	0.000263	0.00573	CcSEcCtD
Lapatinib—Infection—Cisplatin—esophageal cancer	0.000261	0.00569	CcSEcCtD
Lapatinib—Nervous system disorder—Cisplatin—esophageal cancer	0.000258	0.00562	CcSEcCtD
Lapatinib—Skin disorder—Cisplatin—esophageal cancer	0.000255	0.00556	CcSEcCtD
Lapatinib—Cardiac disorder—Capecitabine—esophageal cancer	0.000253	0.00552	CcSEcCtD
Lapatinib—ABCB1—digestive system—esophageal cancer	0.000251	0.00435	CbGeAlD
Lapatinib—Anorexia—Cisplatin—esophageal cancer	0.00025	0.00546	CcSEcCtD
Lapatinib—Angiopathy—Capecitabine—esophageal cancer	0.000247	0.00539	CcSEcCtD
Lapatinib—Immune system disorder—Capecitabine—esophageal cancer	0.000246	0.00537	CcSEcCtD
Lapatinib—Mediastinal disorder—Capecitabine—esophageal cancer	0.000246	0.00536	CcSEcCtD
Lapatinib—Alopecia—Capecitabine—esophageal cancer	0.000241	0.00525	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000239	0.00522	CcSEcCtD
Lapatinib—Mental disorder—Capecitabine—esophageal cancer	0.000239	0.00521	CcSEcCtD
Lapatinib—Malnutrition—Capecitabine—esophageal cancer	0.000237	0.00517	CcSEcCtD
Lapatinib—Neutropenia—Methotrexate—esophageal cancer	0.000237	0.00517	CcSEcCtD
Lapatinib—Dyspnoea—Cisplatin—esophageal cancer	0.000234	0.00511	CcSEcCtD
Lapatinib—Back pain—Capecitabine—esophageal cancer	0.000229	0.005	CcSEcCtD
Lapatinib—Decreased appetite—Cisplatin—esophageal cancer	0.000228	0.00498	CcSEcCtD
Lapatinib—Pneumonia—Methotrexate—esophageal cancer	0.000227	0.00496	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000227	0.00495	CcSEcCtD
Lapatinib—Infestation NOS—Methotrexate—esophageal cancer	0.000226	0.00493	CcSEcCtD
Lapatinib—Infestation—Methotrexate—esophageal cancer	0.000226	0.00493	CcSEcCtD
Lapatinib—Stomatitis—Methotrexate—esophageal cancer	0.00022	0.0048	CcSEcCtD
Lapatinib—Anaemia—Capecitabine—esophageal cancer	0.000219	0.00478	CcSEcCtD
Lapatinib—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000214	0.00466	CcSEcCtD
Lapatinib—Epistaxis—Methotrexate—esophageal cancer	0.000213	0.00465	CcSEcCtD
Lapatinib—Leukopenia—Capecitabine—esophageal cancer	0.000212	0.00463	CcSEcCtD
Lapatinib—ABCB1—lung—esophageal cancer	0.00021	0.00364	CbGeAlD
Lapatinib—Palpitations—Capecitabine—esophageal cancer	0.00021	0.00457	CcSEcCtD
Lapatinib—Cough—Capecitabine—esophageal cancer	0.000207	0.00451	CcSEcCtD
Lapatinib—Arthralgia—Capecitabine—esophageal cancer	0.000202	0.0044	CcSEcCtD
Lapatinib—Myalgia—Capecitabine—esophageal cancer	0.000202	0.0044	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000201	0.00437	CcSEcCtD
Lapatinib—Gefitinib—ABCB1—esophageal cancer	0.000199	0.0298	CrCbGaD
Lapatinib—Hypersensitivity—Cisplatin—esophageal cancer	0.000193	0.00422	CcSEcCtD
Lapatinib—Infection—Capecitabine—esophageal cancer	0.000192	0.00419	CcSEcCtD
Lapatinib—Nervous system disorder—Capecitabine—esophageal cancer	0.00019	0.00414	CcSEcCtD
Lapatinib—Asthenia—Cisplatin—esophageal cancer	0.000188	0.00411	CcSEcCtD
Lapatinib—Cardiac disorder—Methotrexate—esophageal cancer	0.000188	0.00411	CcSEcCtD
Lapatinib—Skin disorder—Capecitabine—esophageal cancer	0.000188	0.0041	CcSEcCtD
Lapatinib—Anorexia—Capecitabine—esophageal cancer	0.000185	0.00402	CcSEcCtD
Lapatinib—Angiopathy—Methotrexate—esophageal cancer	0.000184	0.00401	CcSEcCtD
Lapatinib—Immune system disorder—Methotrexate—esophageal cancer	0.000183	0.004	CcSEcCtD
Lapatinib—Mediastinal disorder—Methotrexate—esophageal cancer	0.000183	0.00399	CcSEcCtD
Lapatinib—Diarrhoea—Cisplatin—esophageal cancer	0.00018	0.00392	CcSEcCtD
Lapatinib—Alopecia—Methotrexate—esophageal cancer	0.000179	0.00391	CcSEcCtD
Lapatinib—Mental disorder—Methotrexate—esophageal cancer	0.000178	0.00388	CcSEcCtD
Lapatinib—Malnutrition—Methotrexate—esophageal cancer	0.000177	0.00385	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000176	0.00385	CcSEcCtD
Lapatinib—Insomnia—Capecitabine—esophageal cancer	0.000175	0.00382	CcSEcCtD
Lapatinib—Dyspnoea—Capecitabine—esophageal cancer	0.000173	0.00376	CcSEcCtD
Lapatinib—Back pain—Methotrexate—esophageal cancer	0.000171	0.00373	CcSEcCtD
Lapatinib—Dyspepsia—Capecitabine—esophageal cancer	0.00017	0.00372	CcSEcCtD
Lapatinib—Decreased appetite—Capecitabine—esophageal cancer	0.000168	0.00367	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000167	0.00365	CcSEcCtD
Lapatinib—Vomiting—Cisplatin—esophageal cancer	0.000167	0.00364	CcSEcCtD
Lapatinib—Fatigue—Capecitabine—esophageal cancer	0.000167	0.00364	CcSEcCtD
Lapatinib—Rash—Cisplatin—esophageal cancer	0.000166	0.00361	CcSEcCtD
Lapatinib—Constipation—Capecitabine—esophageal cancer	0.000166	0.00361	CcSEcCtD
Lapatinib—Dermatitis—Cisplatin—esophageal cancer	0.000165	0.00361	CcSEcCtD
Lapatinib—Anaemia—Methotrexate—esophageal cancer	0.000163	0.00356	CcSEcCtD
Lapatinib—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000158	0.00345	CcSEcCtD
Lapatinib—Leukopenia—Methotrexate—esophageal cancer	0.000158	0.00345	CcSEcCtD
Lapatinib—Nausea—Cisplatin—esophageal cancer	0.000156	0.0034	CcSEcCtD
Lapatinib—Cough—Methotrexate—esophageal cancer	0.000154	0.00336	CcSEcCtD
Lapatinib—Abdominal pain—Capecitabine—esophageal cancer	0.000153	0.00334	CcSEcCtD
Lapatinib—Arthralgia—Methotrexate—esophageal cancer	0.00015	0.00328	CcSEcCtD
Lapatinib—Myalgia—Methotrexate—esophageal cancer	0.00015	0.00328	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000149	0.00326	CcSEcCtD
Lapatinib—Anaphylactic shock—Methotrexate—esophageal cancer	0.000144	0.00314	CcSEcCtD
Lapatinib—ABCB1—lymph node—esophageal cancer	0.000144	0.00249	CbGeAlD
Lapatinib—Infection—Methotrexate—esophageal cancer	0.000143	0.00312	CcSEcCtD
Lapatinib—Hypersensitivity—Capecitabine—esophageal cancer	0.000143	0.00311	CcSEcCtD
Lapatinib—Nervous system disorder—Methotrexate—esophageal cancer	0.000141	0.00308	CcSEcCtD
Lapatinib—Skin disorder—Methotrexate—esophageal cancer	0.00014	0.00305	CcSEcCtD
Lapatinib—Asthenia—Capecitabine—esophageal cancer	0.000139	0.00303	CcSEcCtD
Lapatinib—Anorexia—Methotrexate—esophageal cancer	0.000137	0.003	CcSEcCtD
Lapatinib—Pruritus—Capecitabine—esophageal cancer	0.000137	0.00299	CcSEcCtD
Lapatinib—Diarrhoea—Capecitabine—esophageal cancer	0.000132	0.00289	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000131	0.00286	CcSEcCtD
Lapatinib—Insomnia—Methotrexate—esophageal cancer	0.00013	0.00284	CcSEcCtD
Lapatinib—Dyspnoea—Methotrexate—esophageal cancer	0.000128	0.0028	CcSEcCtD
Lapatinib—Dyspepsia—Methotrexate—esophageal cancer	0.000127	0.00277	CcSEcCtD
Lapatinib—Decreased appetite—Methotrexate—esophageal cancer	0.000125	0.00273	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000124	0.00271	CcSEcCtD
Lapatinib—Fatigue—Methotrexate—esophageal cancer	0.000124	0.00271	CcSEcCtD
Lapatinib—Vomiting—Capecitabine—esophageal cancer	0.000123	0.00268	CcSEcCtD
Lapatinib—Rash—Capecitabine—esophageal cancer	0.000122	0.00266	CcSEcCtD
Lapatinib—Dermatitis—Capecitabine—esophageal cancer	0.000122	0.00266	CcSEcCtD
Lapatinib—Headache—Capecitabine—esophageal cancer	0.000121	0.00265	CcSEcCtD
Lapatinib—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000118	0.00257	CcSEcCtD
Lapatinib—Nausea—Capecitabine—esophageal cancer	0.000115	0.00251	CcSEcCtD
Lapatinib—Abdominal pain—Methotrexate—esophageal cancer	0.000114	0.00248	CcSEcCtD
Lapatinib—Hypersensitivity—Methotrexate—esophageal cancer	0.000106	0.00232	CcSEcCtD
Lapatinib—Asthenia—Methotrexate—esophageal cancer	0.000103	0.00226	CcSEcCtD
Lapatinib—Pruritus—Methotrexate—esophageal cancer	0.000102	0.00222	CcSEcCtD
Lapatinib—Diarrhoea—Methotrexate—esophageal cancer	9.86e-05	0.00215	CcSEcCtD
Lapatinib—Vomiting—Methotrexate—esophageal cancer	9.16e-05	0.002	CcSEcCtD
Lapatinib—Rash—Methotrexate—esophageal cancer	9.09e-05	0.00198	CcSEcCtD
Lapatinib—Dermatitis—Methotrexate—esophageal cancer	9.08e-05	0.00198	CcSEcCtD
Lapatinib—Headache—Methotrexate—esophageal cancer	9.03e-05	0.00197	CcSEcCtD
Lapatinib—Nausea—Methotrexate—esophageal cancer	8.56e-05	0.00187	CcSEcCtD
Lapatinib—EGFR—Signaling Pathways—XIAP—esophageal cancer	1.22e-05	8.24e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—ABL1—esophageal cancer	1.21e-05	8.21e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—KDR—esophageal cancer	1.21e-05	8.2e-05	CbGpPWpGaD
Lapatinib—ERBB4—Disease—PTGS2—esophageal cancer	1.21e-05	8.19e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	1.2e-05	8.16e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—ADH1B—esophageal cancer	1.2e-05	8.1e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—GSTO1—esophageal cancer	1.19e-05	8.09e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—TPI1—esophageal cancer	1.19e-05	8.09e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by NGF—PIK3CA—esophageal cancer	1.19e-05	8.06e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PLCE1—esophageal cancer	1.19e-05	8.05e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—ADH7—esophageal cancer	1.19e-05	8.05e-05	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	1.18e-05	7.99e-05	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—CDKN1A—esophageal cancer	1.16e-05	7.87e-05	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—BCL2—esophageal cancer	1.16e-05	7.87e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—NOTCH1—esophageal cancer	1.16e-05	7.84e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CTNNA1—esophageal cancer	1.15e-05	7.79e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—TGFBR2—esophageal cancer	1.15e-05	7.76e-05	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—CDKN1A—esophageal cancer	1.15e-05	7.75e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—ALDOB—esophageal cancer	1.15e-05	7.75e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CXCL2—esophageal cancer	1.14e-05	7.75e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—TYMP—esophageal cancer	1.14e-05	7.75e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—NOTCH1—esophageal cancer	1.14e-05	7.73e-05	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—ERBB2—esophageal cancer	1.13e-05	7.64e-05	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	1.12e-05	7.6e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—CYP26A1—esophageal cancer	1.11e-05	7.53e-05	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—EP300—esophageal cancer	1.11e-05	7.49e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—GAPDH—esophageal cancer	1.1e-05	7.46e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—CRABP1—esophageal cancer	1.09e-05	7.4e-05	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—EP300—esophageal cancer	1.09e-05	7.38e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—SMAD4—esophageal cancer	1.09e-05	7.34e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—ALOX15—esophageal cancer	1.08e-05	7.34e-05	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—ERBB2—esophageal cancer	1.08e-05	7.34e-05	CbGpPWpGaD
Lapatinib—ERBB2—Disease—CDKN1A—esophageal cancer	1.07e-05	7.27e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PSME2—esophageal cancer	1.07e-05	7.24e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PSME1—esophageal cancer	1.07e-05	7.24e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—ADH1B—esophageal cancer	1.07e-05	7.23e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—ANXA1—esophageal cancer	1.06e-05	7.2e-05	CbGpPWpGaD
Lapatinib—ERBB4—Disease—CDKN1A—esophageal cancer	1.06e-05	7.16e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—CREBBP—esophageal cancer	1.05e-05	7.11e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—ADH1B—esophageal cancer	1.04e-05	7.06e-05	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—EP300—esophageal cancer	1.04e-05	7.04e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—GNG7—esophageal cancer	1.04e-05	7.04e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—SST—esophageal cancer	1.04e-05	7.01e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—GSTO1—esophageal cancer	1.03e-05	7e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—TPI1—esophageal cancer	1.03e-05	7e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—CREBBP—esophageal cancer	1.03e-05	7e-05	CbGpPWpGaD
Lapatinib—ERBB2—Disease—EP300—esophageal cancer	1.02e-05	6.92e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—TYMP—esophageal cancer	1.02e-05	6.91e-05	CbGpPWpGaD
Lapatinib—ABCB1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	1.02e-05	6.91e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—SLC52A3—esophageal cancer	1.01e-05	6.86e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—BLVRB—esophageal cancer	1.01e-05	6.86e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—GHRL—esophageal cancer	1.01e-05	6.83e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—NOTCH3—esophageal cancer	1.01e-05	6.83e-05	CbGpPWpGaD
Lapatinib—ERBB4—Disease—EP300—esophageal cancer	1.01e-05	6.81e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—TYMP—esophageal cancer	9.97e-06	6.75e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—CYP26A1—esophageal cancer	9.94e-06	6.73e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—FBXW7—esophageal cancer	9.93e-06	6.72e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—ALDOB—esophageal cancer	9.92e-06	6.72e-05	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	9.78e-06	6.62e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—ALDH2—esophageal cancer	9.74e-06	6.59e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—CYP26A1—esophageal cancer	9.7e-06	6.56e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—ALOX15—esophageal cancer	9.68e-06	6.55e-05	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—CDKN1A—esophageal cancer	9.65e-06	6.53e-05	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	9.57e-06	6.48e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—GAPDH—esophageal cancer	9.55e-06	6.46e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—CRABP1—esophageal cancer	9.47e-06	6.41e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—ALOX15—esophageal cancer	9.45e-06	6.4e-05	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—EGFR—esophageal cancer	9.43e-06	6.38e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—NOS3—esophageal cancer	9.41e-06	6.37e-05	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—EGFR—esophageal cancer	9.29e-06	6.29e-05	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—CDKN1A—esophageal cancer	9.27e-06	6.27e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—NOS3—esophageal cancer	9.27e-06	6.27e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—GSTT1—esophageal cancer	9.27e-06	6.27e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—GSTO1—esophageal cancer	9.24e-06	6.25e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—TPI1—esophageal cancer	9.24e-06	6.25e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—TLR4—esophageal cancer	9.2e-06	6.23e-05	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—EP300—esophageal cancer	9.19e-06	6.22e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—CYP2A6—esophageal cancer	9.16e-06	6.2e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—NOTCH2—esophageal cancer	9.05e-06	6.13e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—TPI1—esophageal cancer	9.02e-06	6.1e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—GSTO1—esophageal cancer	9.02e-06	6.1e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—GNG7—esophageal cancer	9e-06	6.09e-05	CbGpPWpGaD
Lapatinib—ERBB2—Disease—MYC—esophageal cancer	8.9e-06	6.03e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—HIF1A—esophageal cancer	8.88e-06	6.01e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—ALDOB—esophageal cancer	8.86e-06	5.99e-05	CbGpPWpGaD
Lapatinib—ERBB4—Disease—MYC—esophageal cancer	8.77e-06	5.94e-05	CbGpPWpGaD
Lapatinib—ERBB2—Disease—EGFR—esophageal cancer	8.71e-06	5.89e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—ENO1—esophageal cancer	8.68e-06	5.88e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PTGS1—esophageal cancer	8.68e-06	5.88e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—ERBB2—esophageal cancer	8.67e-06	5.87e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—ALDOB—esophageal cancer	8.64e-06	5.85e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CA1—esophageal cancer	8.62e-06	5.83e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—SLC10A2—esophageal cancer	8.62e-06	5.83e-05	CbGpPWpGaD
Lapatinib—ERBB4—Disease—EGFR—esophageal cancer	8.58e-06	5.81e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PSME1—esophageal cancer	8.56e-06	5.79e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PSME2—esophageal cancer	8.56e-06	5.79e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—GAPDH—esophageal cancer	8.53e-06	5.77e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—CRABP1—esophageal cancer	8.45e-06	5.72e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—ALDH2—esophageal cancer	8.44e-06	5.71e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—GAPDH—esophageal cancer	8.32e-06	5.63e-05	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	8.31e-06	5.62e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—CRABP1—esophageal cancer	8.25e-06	5.58e-05	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—PIK3CA—esophageal cancer	8.19e-06	5.54e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—NOS2—esophageal cancer	8.08e-06	5.47e-05	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—PIK3CA—esophageal cancer	8.06e-06	5.46e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—GNG7—esophageal cancer	8.04e-06	5.44e-05	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	8.04e-06	5.44e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—TGFBR2—esophageal cancer	8.03e-06	5.43e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—GSTT1—esophageal cancer	8.03e-06	5.43e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—NOTCH1—esophageal cancer	8e-06	5.41e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—CYP2A6—esophageal cancer	7.93e-06	5.37e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	7.9e-06	5.35e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—CASP8—esophageal cancer	7.89e-06	5.34e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CA2—esophageal cancer	7.88e-06	5.34e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—CREBBP—esophageal cancer	7.86e-06	5.32e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—GNG7—esophageal cancer	7.84e-06	5.31e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—CCND1—esophageal cancer	7.77e-06	5.26e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—CCND1—esophageal cancer	7.66e-06	5.18e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—SMAD4—esophageal cancer	7.6e-06	5.14e-05	CbGpPWpGaD
Lapatinib—ERBB2—Disease—PIK3CA—esophageal cancer	7.56e-06	5.12e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—ALDH2—esophageal cancer	7.53e-06	5.1e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—ENO1—esophageal cancer	7.52e-06	5.09e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PTGS1—esophageal cancer	7.52e-06	5.09e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—CDKN1A—esophageal cancer	7.52e-06	5.09e-05	CbGpPWpGaD
Lapatinib—ERBB4—Disease—PIK3CA—esophageal cancer	7.45e-06	5.04e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PSME1—esophageal cancer	7.41e-06	5.02e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PSME2—esophageal cancer	7.41e-06	5.02e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—CDKN1A—esophageal cancer	7.41e-06	5.01e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—CYP1B1—esophageal cancer	7.38e-06	5e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—ALDH2—esophageal cancer	7.35e-06	4.97e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—ADH7—esophageal cancer	7.33e-06	4.96e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PLCE1—esophageal cancer	7.33e-06	4.96e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—CREBBP—esophageal cancer	7.25e-06	4.91e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—GSTT1—esophageal cancer	7.16e-06	4.85e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—EP300—esophageal cancer	7.16e-06	4.84e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—CYP2A6—esophageal cancer	7.08e-06	4.79e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	7.05e-06	4.77e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—EP300—esophageal cancer	7.05e-06	4.77e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—GSTT1—esophageal cancer	6.99e-06	4.73e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—CYP19A1—esophageal cancer	6.94e-06	4.7e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—CYP2A6—esophageal cancer	6.91e-06	4.68e-05	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—PIK3CA—esophageal cancer	6.8e-06	4.6e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—BCL2—esophageal cancer	6.77e-06	4.58e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PTGS1—esophageal cancer	6.71e-06	4.54e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—ENO1—esophageal cancer	6.71e-06	4.54e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PSME2—esophageal cancer	6.61e-06	4.48e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PSME1—esophageal cancer	6.61e-06	4.48e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—ERBB2—esophageal cancer	6.58e-06	4.45e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PTGS1—esophageal cancer	6.55e-06	4.43e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—ENO1—esophageal cancer	6.55e-06	4.43e-05	CbGpPWpGaD
Lapatinib—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	6.55e-06	4.43e-05	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—PIK3CA—esophageal cancer	6.53e-06	4.42e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—NOS3—esophageal cancer	6.49e-06	4.4e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	6.47e-06	4.38e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PSME1—esophageal cancer	6.46e-06	4.37e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PSME2—esophageal cancer	6.46e-06	4.37e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—ADH1B—esophageal cancer	6.43e-06	4.35e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—CYP1B1—esophageal cancer	6.39e-06	4.33e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—HMOX1—esophageal cancer	6.33e-06	4.29e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—MYC—esophageal cancer	6.24e-06	4.22e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—HIF1A—esophageal cancer	6.22e-06	4.21e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—TYMP—esophageal cancer	6.14e-06	4.16e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—MYC—esophageal cancer	6.14e-06	4.16e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—EGFR—esophageal cancer	6.1e-06	4.13e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—ABCB1—esophageal cancer	6.08e-06	4.11e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—ERBB2—esophageal cancer	6.07e-06	4.11e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—CYP19A1—esophageal cancer	6.01e-06	4.07e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—EGFR—esophageal cancer	6.01e-06	4.07e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CYP26A1—esophageal cancer	5.98e-06	4.04e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—KDR—esophageal cancer	5.95e-06	4.02e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—PTGS2—esophageal cancer	5.94e-06	4.02e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—ALOX15—esophageal cancer	5.82e-06	3.94e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	5.78e-06	3.91e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—CYP1B1—esophageal cancer	5.71e-06	3.86e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—CDKN1A—esophageal cancer	5.62e-06	3.81e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—NOTCH1—esophageal cancer	5.6e-06	3.79e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—CYP1B1—esophageal cancer	5.57e-06	3.77e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—GSTO1—esophageal cancer	5.56e-06	3.76e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—TPI1—esophageal cancer	5.56e-06	3.76e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—HMOX1—esophageal cancer	5.49e-06	3.71e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	5.38e-06	3.64e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—CYP19A1—esophageal cancer	5.37e-06	3.63e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—EP300—esophageal cancer	5.35e-06	3.62e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—ALDOB—esophageal cancer	5.33e-06	3.6e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—PIK3CA—esophageal cancer	5.29e-06	3.58e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—ABCB1—esophageal cancer	5.27e-06	3.56e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—CYP19A1—esophageal cancer	5.24e-06	3.54e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—PIK3CA—esophageal cancer	5.21e-06	3.53e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—CDKN1A—esophageal cancer	5.19e-06	3.51e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—GAPDH—esophageal cancer	5.13e-06	3.47e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—TP53—esophageal cancer	5.12e-06	3.47e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CRABP1—esophageal cancer	5.08e-06	3.44e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CREBBP—esophageal cancer	5.08e-06	3.44e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—TP53—esophageal cancer	5.04e-06	3.41e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—EP300—esophageal cancer	4.94e-06	3.34e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—HMOX1—esophageal cancer	4.9e-06	3.31e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—GNG7—esophageal cancer	4.83e-06	3.27e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	4.8e-06	3.25e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—HMOX1—esophageal cancer	4.78e-06	3.23e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—ABCB1—esophageal cancer	4.7e-06	3.18e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—NOS3—esophageal cancer	4.55e-06	3.08e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—ALDH2—esophageal cancer	4.53e-06	3.07e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—PIK3CA—esophageal cancer	4.33e-06	2.93e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—GSTT1—esophageal cancer	4.31e-06	2.92e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—MYC—esophageal cancer	4.3e-06	2.91e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CYP2A6—esophageal cancer	4.26e-06	2.88e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—ERBB2—esophageal cancer	4.25e-06	2.88e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—CREBBP—esophageal cancer	4.06e-06	2.75e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—ENO1—esophageal cancer	4.04e-06	2.73e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PTGS1—esophageal cancer	4.04e-06	2.73e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	3.98e-06	2.69e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PSME2—esophageal cancer	3.98e-06	2.69e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PSME1—esophageal cancer	3.98e-06	2.69e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—PIK3CA—esophageal cancer	3.96e-06	2.68e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CCND1—esophageal cancer	3.76e-06	2.54e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—PIK3CA—esophageal cancer	3.65e-06	2.47e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—NOS3—esophageal cancer	3.64e-06	2.46e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CDKN1A—esophageal cancer	3.64e-06	2.46e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	3.55e-06	2.41e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—CREBBP—esophageal cancer	3.52e-06	2.38e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—EP300—esophageal cancer	3.46e-06	2.34e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CYP1B1—esophageal cancer	3.43e-06	2.32e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PTGS2—esophageal cancer	3.33e-06	2.25e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CYP19A1—esophageal cancer	3.23e-06	2.18e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—NOS3—esophageal cancer	3.15e-06	2.13e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—CREBBP—esophageal cancer	3.14e-06	2.13e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—CREBBP—esophageal cancer	3.07e-06	2.08e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—MYC—esophageal cancer	3.01e-06	2.04e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—HMOX1—esophageal cancer	2.94e-06	1.99e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PTGS2—esophageal cancer	2.88e-06	1.95e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—ABCB1—esophageal cancer	2.83e-06	1.91e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—NOS3—esophageal cancer	2.81e-06	1.9e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—EP300—esophageal cancer	2.77e-06	1.87e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—NOS3—esophageal cancer	2.74e-06	1.86e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PTGS2—esophageal cancer	2.57e-06	1.74e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PIK3CA—esophageal cancer	2.56e-06	1.73e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PTGS2—esophageal cancer	2.51e-06	1.7e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—TP53—esophageal cancer	2.48e-06	1.68e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—EP300—esophageal cancer	2.4e-06	1.62e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—EP300—esophageal cancer	2.14e-06	1.45e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—EP300—esophageal cancer	2.09e-06	1.41e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PIK3CA—esophageal cancer	2.05e-06	1.39e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CREBBP—esophageal cancer	1.89e-06	1.28e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PIK3CA—esophageal cancer	1.77e-06	1.2e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—NOS3—esophageal cancer	1.69e-06	1.14e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PIK3CA—esophageal cancer	1.58e-06	1.07e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PTGS2—esophageal cancer	1.55e-06	1.05e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PIK3CA—esophageal cancer	1.54e-06	1.05e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—EP300—esophageal cancer	1.29e-06	8.71e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PIK3CA—esophageal cancer	9.52e-07	6.44e-06	CbGpPWpGaD
